Abstract: An intelligent electromagnetic induction heating leveling system, comprising: a trolley type leveler, an unmanned aerial vehicle temperature measurement device, indoor positioning devices used for converting position information of a trolley of the trolley type leveler and the unmanned aerial vehicle temperature measurement device into position parameters, and a control system. The system can perform, according to preset data parameters, data transmission by means of a wireless local area network and the unmanned aerial vehicle temperature measurement device and control the unmanned aerial vehicle temperature measurement device to move to a specified position. The system intelligently controls the leveling temperature and leveling time of a leveling area, and thus may be suitable for leveling of weld joints having different sizes and depths, and achieve a good leveling effect. Also provided is an intelligent electromagnetic induction heating leveling method.

Abstract: An intelligent electromagnetic induction heating leveling system, comprising: a trolley type leveler, an unmanned aerial vehicle temperature measurement device, indoor positioning devices used for converting position information of a trolley of the trolley type leveler and the unmanned aerial vehicle temperature measurement device into position parameters, and a control system. The system can perform, according to preset data parameters, data transmission by means of a wireless local area network and the unmanned aerial vehicle temperature measurement device and control the unmanned aerial vehicle temperature measurement device to move to a specified position. The system intelligently controls the leveling temperature and leveling time of a leveling area, and thus may be suitable for leveling of weld joints having different sizes and depths, and achieve a good leveling effect. Also provided is an intelligent electromagnetic induction heating leveling method.

Abstract: The present invention relates to a NMDA receptor antagonist and use thereof. The NMDA receptor antagonist of the present invention is a compound of formula I below, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a tautomer, a solvate, an isotopic substituent, a polymorphic substance, a prodrug or a metabolite thereof. In the formula, ring A, ring B, and R2 are as described herein. The present invention also provides a pharmaceutical composition comprising these compounds, and use of these compounds in the preparation of a drug for treating or preventing NMDA receptor-mediated diseases.

Abstract: A method for extracting and isolating a lutein crystal from a vegetable oil resin containing a lutein diester, comprises: dissolving lipase into deionized water to form an enzyme solution; dissolving a lutein extract into an alcohol solvent containing the deionized water to form a uniform alcohol solution; adding the enzyme solution to the alcohol solution for performing hydrolysis, and stirring same to obtain a lutein solution; filtering and performing filtration isolation on the lutein solution to obtain a crystalline; re-dissolving the crystalline into a non-polar organic solvent, and using deionized water for washing a water-soluble impurity; recycling and cooling the organic solvent to obtain a recrystallization; and isolating and drying the recrystallization to obtain the lutein crystal. In this method, selectivity is strong, reaction time is short, no waste water is produced, process is environment-friendly and suitable for industrial production, and obtained lutein crystal is high in purity and yield.

Abstract: Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.

Abstract: Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.

Abstract: Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.

Abstract: The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.